# Sanofi

> Sanofi is a Paris-headquartered, publicly traded biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines and vaccines. After separating its Opella consumer-health business, it is concentrating capital and scientific work on immunology, vaccines, rare diseases, neurology and oncology, supported by AI-enabled discovery and a global manufacturing network. Its customers and users span patients, clinicians, hospitals, pharmacies, wholesalers, governments and public-health agencies in roughly 60 countries.

- **Founded:** 1973
- **Headquarters:** Paris, France
- **Founders:** Jean-René Sautier (Co-founder and founding chairman), Jean-François Dehecq (Co-founder and founding managing director)
- **Team size:** More than 74,000 employees across roughly 60 countries
- **Products:** Dupixent (dupilumab), Beyfortus (nirsevimab), ALTUVIIIO (efanesoctocog alfa), Sarclisa / Sarclisa Escena (isatuximab), Tzield (teplizumab)
- **Notable:** Built a vaccine portfolio that protects about 500 million people each year., Operates 37 production sites that collectively manufacture roughly 2 billion medicine and vaccine doses annually., Recorded €43.626 billion in 2025 net sales, up 9.9% at constant exchange rates.

## Products & services

- **Dupixent (dupilumab)** — A Regeneron-partnered biologic targeting IL-4 and IL-13 signaling, approved across multiple type 2 inflammatory diseases and Sanofi's largest medicine by sales.
- **Beyfortus (nirsevimab)** — A long-acting monoclonal antibody, developed with AstraZeneca, that helps protect infants against RSV lower respiratory tract disease.
- **ALTUVIIIO (efanesoctocog alfa)** — A once-weekly factor VIII replacement therapy for hemophilia A, developed with Sobi.
- **Sarclisa / Sarclisa Escena (isatuximab)** — An anti-CD38 oncology medicine for multiple myeloma; the 2026 US on-body injector approval enables subcutaneous administration.
- **Tzield (teplizumab)** — A disease-modifying therapy for type 1 diabetes, first approved to delay stage 3 disease and expanded in the US in 2026 for recently diagnosed patients.
- **Rare-disease medicines** — A portfolio spanning enzyme-replacement and other therapies, including Fabrazyme, Cerezyme, Nexviazyme, Xenpozyme, Cablivi, Qfitlia and Wayrilz.
- **Vaccines** — Pediatric, influenza, meningococcal, travel and endemic-disease vaccines, including MenQuadfi, Fluzone, Flublok and Nuvaxovid commercialization.
- **Clinical development and manufacturing platforms** — AI-assisted discovery, clinical-trial operations and a 37-site network producing small molecules, biologics, vaccines and devices for Sanofi's portfolio and partners.

## Achievements

- Built a vaccine portfolio that protects about 500 million people each year.
- Operates 37 production sites that collectively manufacture roughly 2 billion medicine and vaccine doses annually.
- Recorded €43.626 billion in 2025 net sales, up 9.9% at constant exchange rates.
- Grew Dupixent into its largest medicine, with 2025 sales of approximately €15.7 billion.
- Established enzyme-replacement therapies for rare lysosomal storage disorders including Gaucher, Fabry and Pompe diseases.
- Received ten regulatory approvals in 2025 and launched Qfitlia, Wayrilz and Nuvaxovid.
- Expanded MenQuadfi's EU indication in August 2026 to infants from six weeks of age.
- Reported a 77-project clinical-stage pipeline in 2026, including 34 phase 3 or registration-stage projects.

## Latest updates

- **2026-08** — The European Commission expanded MenQuadfi's indication to infants from six weeks of age.
- **2026-07** — Second-quarter sales rose 17.8% at constant exchange rates; Sanofi upgraded 2026 sales-growth guidance to around 10% at constant exchange rates.
- **2026-07** — Sanofi decided not to pursue global regulatory submissions for amlitelimab in atopic dermatitis and discontinued selected programs as part of pipeline prioritization.
- **2026-07** — The FDA approved Sarclisa Escena, an on-body injector formulation for multiple myeloma.
- **2026-06** — Sanofi named Paulo Fontoura global head of pharma R&D, effective September 2026.
- **2026-05** — Belén Garijo became chief executive officer, beginning a new execution and pipeline-review phase.
- **2026-01** — Sanofi reported €43.626 billion in 2025 net sales and said profitable growth was expected to continue in 2026.

## Links

- Website: https://www.sanofi.com
- LinkedIn: https://www.linkedin.com/company/sanofi
- Twitter/X: https://x.com/sanofi
- YouTube: https://www.youtube.com/@Sanofi
- Instagram: https://www.instagram.com/sanofi/
- Facebook: https://www.facebook.com/Sanofi
- TikTok: https://www.tiktok.com/@sanofi

---

Profile page: https://yespress.io/sanofi
Published by YesPress — https://yespress.io
Last updated: 2026-08-11